Background
==========

Atrial septal defect (ASD) is the most common subtype of congenital heart disease (CHD), and its prevalence can reach between 8.93--10.6 per 1,000 live births in China \[[@b1-medscimonit-24-1340],[@b2-medscimonit-24-1340]\]. ASD can lead to several clinical complications, including infective endocarditis, chronic heart failure, and repeated lung infection, which can severely affect the physical and psychological health of affected patients \[[@b3-medscimonit-24-1340]\]. The process of cardiac development is regulated by several genes and is precisely controlled; any disruption in cardiac development can cause congenital cardiac defects. Gene mutations have been shown to play important roles in the etiology and pathogenesis of ASD, including mutations in *NKX2-5, GATA4, MYH6,* and*TBX5* \[[@b4-medscimonit-24-1340],[@b5-medscimonit-24-1340]\]. However, some genetic variants associated with sporadic ASD remain to be identified.

Whole-exome sequencing (WES) is a powerful and efficient tool to obtain sequencing information on the whole exome with high resolution and low cost \[[@b6-medscimonit-24-1340]\]. Due to the limitations in current knowledge of the genomic noncoding regions, many recent studies have only focussed on the identification of pathogenic mutations in protein coding regions by using WES \[[@b7-medscimonit-24-1340]\]. The rapid development in the techniques used in WES has shed light on the complex mechanisms involved in several forms of CHD, including patent ductus arteriosus (PDA), familial ASD, and ventricular septal defect (VSD) \[[@b8-medscimonit-24-1340]\]. However, few studies have studied the mutations associated with the etiology and pathogenesis of sporadic ASD. Therefore, there is a need to extend studies on the spectrum of ASD-related mutations using WES and to provide a foundation for further functional analysis, which may further clarify the gene associations, the pathogenesis, and possibly lead to new diagnostic markers for sporadic ASD.

The aim of this study was to use WES combined with bioinformatics analysis to identify novel gene variants in cases of sporadic congenital ASD, followed by validation by Sanger sequencing and a multiplexed MassARRAY system.

Material and Methods
====================

Study participants and collection of tissue samples
---------------------------------------------------

All participants in this study were from the Chinese population and were enrolled by the Department of Cardiovascular Surgery of Yan'an Affiliated Hospital of Kunming Medical University. Five Han patients with secundum atrial septal defect (ASD) were recruited, and their tissue samples were collected for whole-exome sequencing (WES). To confirm the WES findings, verification was conducted by Sanger sequencing with tissue samples and blood samples from the same five patients with sporadic ASD. For further evaluation, 452 additional patients with sporadic secundum ASD (212 male and 240 female patients) and 519 healthy subjects (252 male and 267 female subjects) were recruited, and the blood samples were obtained for further verification using a multiplexed MassARRAY system.

The study was approved by the Medical Ethics Committee of Kunming Medical University. Informed consent was signed by each study participant or their legal guardians to participate in the study. The diagnosis of the ASD was based on echocardiography and during routine surgery for ASD surgical repair. Details of the clinical characteristics of the study participants are shown in [Supplementary Table 1](#s7-medscimonit-24-1340){ref-type="supplementary-material"}.

The clinical data of the five patients with isolated ASD
--------------------------------------------------------

Case 1: A female patient aged 6 months was found to have a grade 3/6 systolic murmur in the second left parasternal space and fixed splitting of the second heart sound. Left-to-right shunting was detected by echocardiogram and the diameter of the defect in the atrial septum was 22 mm.

Case 2: A male patient aged 13 months was found to have a grade 2/6 systolic murmur in the second left parasternal space. Left-to-right shunting was detected by echocardiogram and the diameter of the defect in the atrial septum was 10 mm.

Case 3: A female patient aged 19 months was found to have a grade 2/6 systolic murmur in the second left parasternal space and fixed splitting of the second heart sound. Left-to-right shunting was detected by echocardiogram and the diameter of the defect in the atrial septum was 16 mm.

Case 4: A female patient aged 23 months was found to have a grade 2/6 systolic murmur in the second left parasternal space and fixed splitting of the second heart sound. Left-to-right shunting was detected by echocardiogram and the diameter of the defect in the atrial septum was 12 mm.

Case 5: A male patient aged 17 months was found to have a grade 2/6 systolic murmur in the second left parasternal space and fixed splitting of the second heart sound. Left-to-right shunting was detected by echocardiogram and the diameter of the defect in the atrial septum was 11 mm.

The secundum ASD of the five patients with isolated ASD was further confirmed during the ASD repair surgery, performed through a median sternotomy, under cardiopulmonary bypass. Atrial septal tissue samples from the five patients with ASD were collected from the rims of the defect in the atrial septum. The collected tissue samples were stored at −80°C. Serum was extracted from blood and stored at −80°C.

None of the five patients had a family history of congenital heart disease (CHD), Down's syndrome, or Marfan's syndrome. Patients with other common developmental defects or chromosomal abnormalities were excluded from this study. The 519 healthy subjects were recruited from the Department of Health Examination Centers of Yan'an Affiliated Hospital of Kunming Medical University. Echocardiograms, dynamic electrocardiograms, treadmill exercise tests, measurements of blood pressure and blood lipids were performed to exclude cardiovascular disease, including coronary artery disease, hypertension, and arrhythmias.

Whole-exome sequencing
----------------------

Genomic DNA of tissue samples from five patients with ASD was extracted using Thermo DNA and the Lab-Serv Cell and Tissue DNA Extraction Kit (Thermo Scientific). The purity and quality of DNA from the samples were evaluated using an ultramicro-spectrophotometer (SpectraMax QuickDrop), and the optical density (OD) value of DNA was identified as between 1.8--2.0. Then the DNA was aliquoted and preserved in 0.5mL Eppendorf tubes at −80°C for WES. The enrichment of exon was performed by Agilent Sure Select Human All Exon V5 Kit (Agilent, USA) from 1.0 ug genomic DNA according to the manufacturer's protocol. First, the genomic DNA was broken randomly into 150--200bp fragments. Then, the DNA libraries were prepared by the addition of "A" bases to the 3′ end of the DNA fragment. Finally, the DNA libraries were assessed for quality control and sequenced by Illumina Hiseq 2500 Sequencer ([Supplementary Figure 1](#s1-medscimonit-24-1340){ref-type="supplementary-material"}).

Mapping to reference sequences
------------------------------

All single nucleotide variants (SNVs) of each sample were obtained by comparing the valid sequencing data with the human reference genome (UCSC Genome Browser hg19) using Burrows-Wheeler Aligner (BWA) software \[[@b9-medscimonit-24-1340]\] to gain the primary mapping results. Then, the aligned data were sorted by SAMtools \[[@b10-medscimonit-24-1340]\] to select the best mapping positions, and the duplicated reads were marked by Picard (*<http://sourceforge.net/projects/picard/>*) so that they could be used in the next analysis.

Annotation, data filtering, and gene ontology analysis
------------------------------------------------------

Functional annotation was conducted to find the genetic variation associated with ASD. First, all variants were annotated using the ANNOVAR software tool \[[@b11-medscimonit-24-1340]\]. Then, the normal population variant databases, including 1,000 Genomes Project (version 2012), the Single Nucleotide Polymorphism database (DbSNP) (version 138), and the National Heart, Lung, and Blood Institute (NHLBI) database, were performed to exclude the common variations occurring with no more than 1% minor allele frequency (MAF) and variants not related to congenital heart disease (CHD). Then, the rare variants obtained in the previous step were further analyzed using the Venn analysis, gene ontology (GO) analysis, and literature review and protein database (*<http://www.uniprot.org/>* and *<http://www.genecards.org/>*) to classify the variants associated with cardiac development or ASD. GO analysis was applied to analyze the main function of SNVs according to the GO which was the key functional classification of the National Center for Biotechnology Information (NCBI). The genes of the Gene Ontology (GO) term enrichment analysis included the following: GO.0048739_cardiac muscle fiber development, GO.0003143_embryonic heart tube morphogenesis, GO.0003300_cardiac muscle hypertrophy, GO.0001539_cilium or flagellum-dependent cell motility, GO.0055008_cardiac muscle tissue morphogenesis, GO.0060038_cardiac muscle cell proliferation, GO.0060956_endocardial cell differentiation, GO.0007512_adult heart development, GO.0003007_heart morphogenesis and GO.0030509_BMP signaling pathway.

Candidate susceptible variants and gene selection
-------------------------------------------------

The SIFT \[[@b12-medscimonit-24-1340]\], PolyPhen-2 \[[@b13-medscimonit-24-1340]\] and MutationTaster \[[@b14-medscimonit-24-1340]\] were performed to predict whether the substitution of amino acid affected the function of the protein. Based on the degree of CHD, the mutation was selected as candidate susceptible variant if one of the three software showed it was pathological. Subsequently, the expression level of the corresponding genes of the candidate variants was selected via genecards (*<http://www.genecards.org>*).

Variant validation and statistical analysis
-------------------------------------------

Mutation validation was initially conducted by Sanger sequencing. Sanger sequencing was performed using genomic DNA from both tissue samples and peripheral blood of the same five patients with ASD recruited for WES. The mutations in both tissue samples and blood samples were selected as positive variants. Additionally, the positive variants were consistent with corresponding data from WES and were further tested using the multiplexed MassARRAY analysis in large-scale samples. The primers involved in MassARRAY were designed using AssayDesigner 3.1. The sequences of the primers are listed in [Supplementary Table 2](#s8-medscimonit-24-1340){ref-type="supplementary-material"}.

The genomic DNA was amplified under the following conditions: initial denaturation, 94°C for 15 min, then 45 cycles of 94°C for 20 s, 56°C for 30 s and 72°C for 60 s, followed by 72°C for 3 min. The final products were preserved at 4°C for Shrimp alkaline phosphatase (SAP) purification reaction to remove unincorporated dinucleotide triphosphates (dNTPs). The products were purified under the following conditions: 37°C for 40 min, 85°C for 5 min, the products were preserved at 4°C for extension polymerase chain reaction (PCR).

The conditions of extension PCR were listed as follows: 94°C for 30 s, 94°C for 5 s, then 40 cycles of 52°C for 5 s, 5 cycles of 80°C for 5 s, followed by 72°C for 3 min. The final products were preserved at 4°C for further analysis. The products and water were robotically dispensed into 384 sample plate and mass spectra were collected by the multiplexed MassARRAY compact matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) analyzer. The MassARRAY analysis was performed by EpiTYPER (Version: 4.0). The frequencies of the mutations were calculated by the χ^2^ test or Fisher exact test using SPSS version 22.0 (IBM, USA). P\<0.05 represented statistical significance.

Results
=======

Clinical characteristics of five patients with sporadic atrial septal defect (ASD)
----------------------------------------------------------------------------------

Five patients with secundum atrial septal defect (ASD) diagnosed by echocardiogram were recruited into the study. The diameter of the defects in the atrial septum ranged from 10 mm to 22 mm ([Table 1](#t1-medscimonit-24-1340){ref-type="table"}). Except for ASD, other cardiac structural abnormalities and congenital anomalies were not found in these five patients. ASD was not diagnosed in other family members, which ensured that all patients included in this study had sporadic ASD.

Overview of whole-exome sequencing (WES) data
---------------------------------------------

The total raw reads of ASD samples ranged from 17.57--28.46 million. More than 95% of the sequenced bases showed a quality score of ≥Q20. The raw sequencing data yielded an average of 5000 Mb of effective data and the average depth of the target areas was over 60 × coverage. The quality and depth of target areas are listed in [Supplementary Figure 2](#s2-medscimonit-24-1340){ref-type="supplementary-material"} and [Supplementary Table 3](#s9-medscimonit-24-1340){ref-type="supplementary-material"}.

In total, 181,762 genomic variants in five samples from patients with isolated ASD were identified. There were an average of over 20,000 heterozygous variants and 15,000 homozygous variants in the samples ([Supplementary Table 4](#s10-medscimonit-24-1340){ref-type="supplementary-material"}). The circos map is shown to demonstrate the distributions of the variants on the chromosomes ([Supplementary Figure 3](#s3-medscimonit-24-1340){ref-type="supplementary-material"}).

Identification of 33 ASD-associated gene variants by bioinformatics analysis
----------------------------------------------------------------------------

The advanced bioinformatic analysis was performed to identify the single nucleotide variants (SNVs) associated with ASD ([Figure 1](#f1-medscimonit-24-1340){ref-type="fig"}). The 181,762 SNVs from the five patients were filtered by 1,000 Genome, the Single Nucleotide Polymorphism database (DbSNP), and the National Heart, Lung, and Blood Institute (NHLBI) database. After filtering, there were 713 rare variants, and the distribution of the rare variants on chromosomes was presented by circus map ([Supplementary Figure 3](#s3-medscimonit-24-1340){ref-type="supplementary-material"}, [Supplementary Table 4](#s10-medscimonit-24-1340){ref-type="supplementary-material"}). Furthermore, through performing Venn analysis, GO analysis and literature review, 13, 21 and 20 pathogenic variants perhaps involved in heart development were obtained ([Supplementary Figure 4](#s4-medscimonit-24-1340){ref-type="supplementary-material"}, [Supplementary Tables 5](#s11-medscimonit-24-1340){ref-type="supplementary-material"}[](#s12-medscimonit-24-1340){ref-type="supplementary-material"}--[7](#s13-medscimonit-24-1340){ref-type="supplementary-material"}). Also, the genes that overlapped and or were only minimally expressed in the heart were excluded from the present study. Finally, 33 variants in 25 genes were chosen for further analysis ([Table 1](#t1-medscimonit-24-1340){ref-type="table"}).

Validation and exploration of novel ASD variants
------------------------------------------------

The 33 ASD-associated variants selected in the above step were further validated by Sanger sequencing in samples from the atrial septum and the peripheral blood ([Supplementary Figure 5](#s5-medscimonit-24-1340){ref-type="supplementary-material"}). The findings showed that the mutations of 33 *loci* were consistent with corresponding data from WES, verifying the accuracy and reliability of WES findings. The consistency of mutations in tissue samples and blood samples not only confirmed our results but also excluded somatic mutations. Then, the multiplexed MassARRAY analysis was performed to verify the 33 variants in additional 452 samples from patients with ASD, and 519 samples from healthy subjects.

The results showed that nine variants were positive mutations, which were respectively located in nine genes. The variants were: 138665410 (NM_023067_c.C155G) in *FOXL2*, 23862952 (NM_002471: c.G2851T) in *MYH6*, 71098693 (NM_001198542: c.A2207C) in *HYDIN*, 88600890 (NM_153813: c.G2524A) in *ZFPM*, 39913231 (NM_001123384: c.T4728G) in *BCOR*, 156186376 (NM_001128209: c.A845G) in *SGCD*, 61708404 (NM_003400: c.G2985C) in *XPO1*, 65652097 (NM_004214: c.G850A) in *FIBP*, 179480499 (NM_003319: c.C21134G) in *TTN* ([Supplementary Table 2](#s8-medscimonit-24-1340){ref-type="supplementary-material"}).

Also, three mutations with a high mutation frequency were found to be significantly associated with ASD (P\<0.05), including 138665410 in the*FOXL2* gene (26.11%), 23862952 in the *MYH6* gene (2.43%), 71098693 in the *HYDIN* gene (3.10%) ([Figure 2](#f2-medscimonit-24-1340){ref-type="fig"}, [Supplementary Table 2](#s8-medscimonit-24-1340){ref-type="supplementary-material"}). Among these loci, variants in the *FOXL2* gene and the *MYH6* gene were only found in patients with ASD (P\<5×10^−4^), and variants in the *FOXL2* gene and the *HYDIN* gene were first identified in isolated ASD. No significant difference in the other six variants were found between patients with ASD and healthy subjects (P\>0.05) ([Figure 3](#f3-medscimonit-24-1340){ref-type="fig"}, [Supplementary Table 2](#s8-medscimonit-24-1340){ref-type="supplementary-material"}). The location of the three variants was found to be in located in a region that is highly conserved among species ([Supplementary Figure 6](#s6-medscimonit-24-1340){ref-type="supplementary-material"}).

Discussion
==========

The etiology of congenital heart disease (CHD), including atrial septal defect (ASD), is complex and associated with both environmental and genetic factors. Epidemiological data has shown that environmental factors, including viral infection during pregnancy, can increase the risk of CHD, but that the genetic causes are mainly associated with CHD \[[@b15-medscimonit-24-1340]\]. The role of genomic variants in CHD, with rare mutations in cardiac genes, are more likely to result in CHD, including in sporadic ASD \[[@b4-medscimonit-24-1340],[@b5-medscimonit-24-1340]\]. Therefore, the aim of this study was to use whole-exome sequencing (WES) combined with bioinformatics analysis to identify novel genetic variants in cases of sporadic congenital ASD, followed by validation by Sanger sequencing.

In the present study, 181,762 genomic variants were identified by the WES approach. To the best of our knowledge, this is the first study to identify exon mutations associated with ASD by WES in sporadic ASD. Through verification by Sanger sequencing and MassARRAY, three *loci* were identified, 138665410 in the *FOXL2* gene, 71098693 in the *HYDIN* gene, and 23862952 in the *MYH6* gene, with high mutation frequency, likely to be associated with ASD. Also, two variants, 138665410 (NM_023067_c.C155G) in the *FOXL2* gene and 71098693 (NM_001198542: c.A2207C) in the *HYDIN* gene were identified for the first time in ASD. The following variants, 138665410 (NM_023067_c.C155G) in the*FOXL2* gene and 23862952 (NM_002471: c.G2851T) in the *MYH6* gene were only found in ASD in this study. These findings probably represent disease-associated mutations for sporadic ASD.

The*FOXL2* gene acts as an important transcription factor belonging to the winged helix/forkhead transcription factor family, including Foxa2, Foxc1/c2 and Foxos \[[@b16-medscimonit-24-1340]\]. These family members have been identified as crucial components of the signaling pathways for controlling cardiogenesis and embryonic cardiac development \[[@b16-medscimonit-24-1340]\]. Previous studies have shown that FOXL2 protein was expressed in several tissues, including the heart \[[@b16-medscimonit-24-1340]--[@b19-medscimonit-24-1340]\]. However, the role of the *FOXL2* gene has not been well studied in ASD. In the present study, we found that the mutation frequency of 138665410 variant (NM_023067_c.C155G) in *FOXL2* gene was 26.11%, the G\>C mutation was found in 118 cases with ASD but not in healthy subjects. The mutation frequency was significantly different between patients with ASD and healthy subjects (P\<5×10^−4^). The variant in *FOXL2* that resulted in a replacement of alanine by glycine might affect atrial septum morphogenesis. The mechanism of the involvement of*FOXL2* in ASD remains to be elucidated.

Previously published studies have shown that the activation of aberrant Notch signaling was induced the down-regulation of *FOXL2* expression during the development of the eyelid levator muscle \[[@b20-medscimonit-24-1340]\]. Also, the Notch signaling pathway has been shown to participate in the development of the heart, while abnormal Notch signaling might cause aberrant atrioventricular canal, proximal outflow tract and coronary system development \[[@b21-medscimonit-24-1340],[@b22-medscimonit-24-1340]\]. Therefore, it may be speculated that the function of *FOXL2* during atrioventricular canal and proximal outflow tract formation is Notch signaling-dependent, but the specific mechanisms of *FOXL2* mutations participating in the ASD development require further investigation.

The *MYH6* gene encodes the alpha heavy chain subunit of cardiac myosin, which is a fast ATP-ase that is primarily expressed in atrial tissue, and plays a crucial role in muscle contraction and sarcomeric structure, with studies showing that aberrant expression of*MYH6* ablated the atrial septal formation, and mutation of *MYH6* contributed to ASD development \[[@b23-medscimonit-24-1340]--[@b25-medscimonit-24-1340]\]. In the present study, the 23862952 variant of the *MYH6* gene (NM_002471: c.G2851T) was found in patients with ASD but not in healthy subjects (P\<5×10^−4^). The mutation was localized in the 22^nd^ exon of *MYH6* gene, which resulted in a shift of the open reading frame (ORF), termination of protein synthesis, and loss of 988 amino acids by the premature stop codon. Due to this variant, a highly conserved amino acid was altered in the myosin tail domain, which led to the loss of about 95% of tail domains of *MYH6*. This mutation in the *MYH6* gene might affect the development of the atrial septum, explaining its involvement in the pathogenesis of ASD.

The *HYDIN* gene is localized on the chromosome 16 (16q22.2) and encodes an axonal and cilial protein \[[@b26-medscimonit-24-1340]\]. This gene has been predominantly found in the fetal heart and bronchial ciliated epithelia \[[@b27-medscimonit-24-1340]\], and mutations in the *HYDIN* gene have been shown to impair ciliary motility in a mouse model \[[@b28-medscimonit-24-1340]\]. A large-scale mouse mutagenesis screening study showed that primary cardiac cilia were required in formation and development of endocardial cushions during embryogenesis \[[@b29-medscimonit-24-1340]\]. A high rate of ciliary dysfunction and mutations in cilia-related pathways have also been identified in mice with cardiac defects \[[@b29-medscimonit-24-1340]\]. However, the role of the *HYDIN* gene has not previously been well studied in human ASD. However, in this study, a novel mutation, the 71098693 variant (NM_001198542: c.A2207C) in the *HYDIN* gene was identified in patients with ASD, and its mutation frequency was significantly different between patients with ASD compared with healthy subjects (P\<0.05). This variant caused a replacement of alanine by cysteine with charge modification, which may result in the mutation in the *HYDIN* gene disabling ciliary motility that affects the formation of endocardial cushions in cardiac embryogenesis. However, the exact function of *HYDIN* during atrial septum morphogenesis remains unknown.

Genomic studies rely on precision, reliability, and reproducibility with reliable methods of identification and analysis. In the current study, a combination of WES and generation sequencing was used to reduce the risk of false-positive results. In the selection of susceptible and reliable genetic variants related to ASD, the study design included five main steps. To exclude the interference of familial and syndromic ASD, sporadic cases of ASD were included. The use of WES yielded an average of 5000 Mb of data and the average depth of the target area was \>60× coverage, with more than 95% of the sequenced bases shown to have a quality score of ≥Q20, reflecting the accuracy of sequencing and the quality of samples in the study. The process of gene mutation filtering was performed as rigorously as possible, using the 1,000 Genomes Project, the Single Nucleotide Polymorphism database (DbSNP), and the National Heart, Lung, and Blood Institute (NHLBI) databases to exclude the common variants occurring with more than 1% minor allele frequency (MAF). Through a series of analyses that included Venn analysis, gene ontology (GO) analysis, and literature review, and the use of three predictive bioinformatics software programs, including SIFT \[[@b12-medscimonit-24-1340]\], PolyPhen-2 \[[@b13-medscimonit-24-1340]\], and MutationTaster \[[@b14-medscimonit-24-1340]\], it was possible to classify the variants associated with cardiac development or CHD and their potential impact on the function of proteins. To exclude false-positive variants, Sanger sequencing was performed, which showed that mutations from 33 *loci* were consistent with corresponding data from WES, which verified the accuracy and supported the reliability of the WES findings. Finally, the fifth important consideration in the study design was confirmation of the findings based on validation using large-scale clinical populations with ASD by using multiplexed MassARRAY analysis.

This study had several limitations. Because WES allowed the amplification of between 80--90% of all coding exons, some gene exons may have been missed in the process of sequencing. Also, WES cannot be performed to identify deep intronic mutations and is not an effective method to test for large genomic events, such as gene deletions and insertions.

Conclusions
===========

The present study was the first study that demonstrated variants in the *FOXL2* and the *HYDIN* genes were associated with sporadic atrial septal defect (ASD), and supported the use of whole-exome sequencing (WES), Sanger sequencing, and bioinformatics analysis to identify disease-associated mutations. The results showed that mutations in the *FOXL2, MYH6* and *HYDIN* genes were associated with cases of ASD and that the presence of mutations in the *FOXL2*, *MYH6*, and *HYDIN* genes might contribute to the etiology of sporadic cases of ASD.

Supplementary data
==================

###### 

Schematic of gene library construction, capture, and sequencing.

###### 

The depth of the target areas. (**A**) Sequence depth of the sample. (**B**) Cumulative sequence depth of the sample. (**C**) The depth of coverage (left coordinate) and the ratio of coverage (right coordinate) on the chromosome.

###### 

The circos map provided to demonstrate the distributions of the variants on the chromosomes. Red -- ASD-1; Green -- ASD-2; Blue -- ASD-3; Yellow -- ASD-4; Black -- ASD-5. (**A**) Rare variants before filtering. (**B**) Rare variants after filtering.

###### 

Thirteen variants were obtained by Venn analysis.

###### 

Thirty-three variants were confirmed by Sanger sequencing. Sanger sequencing demonstrates that all of the variants were heterozygous. The variants are marked using red arrows.

###### 

The conservation of different orthologs presented for the three associated variants in the *HYDIN*, *FOXL2*, and *MYH6* genes

###### 

Characteristics of 5 ASD patients.

  Number of sample   Gender   Age         Diagnosis and diameter
  ------------------ -------- ----------- ------------------------
  ASD-1              Female   6 months    Secundum ASD, 22 mm
  ASD-2              Male     13 months   Secundum ASD, 10 mm
  ASD-3              Female   19 months   Secundum ASD, 16 mm
  ASD-4              Female   23 months   Secundum ASD, 12 mm
  ASD-5              Male     17 months   Secundum ASD, 11 mm

###### 

Sequences of the primers involved in Mass-Array.

  Variants under test   Forward (5′-3′)            Reverse (3′-5′)          Product (bp)
  --------------------- -------------------------- ------------------------ --------------
  23871923              AGCTTGTAGACGCCAGCTTT       CTGGGTTCACTCCTTGGTCC     433
  33573776              ACAGCCAGCTGAACATACCC       GGGATGTCAGAGGGGAAACG     281
  55371905              CGCAAGCAGGTGAA             CCAGCGTAGTCCGAGA         359
  61708404              TATCCGAATAACATCTC          GAATGTCTTGAACCC          450
  70952188              TGGGGACTGCAAAGGTTGTT       ATCGTCTCCTACCCGGTGAA     420
  131756681             ATGAAGTGACCACCAAA          GAGAAGACCACAGAGCC        390
  138665410             GGTCCAGCGTCCAGTAGTTGC      GCACAGTCAAGGAGCCAGAAGG   330
  146684019             TCTATTAGCACCAATCACC        GAAGTTCAAAGGGCAGTA       315
  176638008             AAAACCAGGGATTCAAGT         CAGTAAGCCAGGTAGGGA       465
  228467050             ATGGTTTGCCCTACACTCCT       TGTCCTCTTGTGGCTCTGC      89
  65652097              GACCAGGTTGGGTGTCAGAG       GGGACTTGGTTGATGGAGGG     248
  88600725              CCACGAGACCTACACCG          CCAGGCGGAAATGCT          545
  117156600             GACAAGAGGCTCAGAGGG         CTGTGGCTTTGTGACTGC       479
  179435002             AATGCCTTCTTTATCCCG         AACCAGCCGCTTAGTTTG       310
  179480499             CCCATAACTTCAACTCTA         ACACCTCATTTGCCATCT       461
  23862952              GCTGCTCCAGCTTGACCTTA       TCTCCTCCCCTCCCCTAGAT     686
  41545061              CCTCTTCAGCCCTCTTCACC       GAGACACTGGAGCTTGACCG     281
  71098693              GAACTCACCTGAGGCTGGAC       GTATCTCGCTTGGGGCTCTG     224
  71576338              ACTTCAAAGGCCACGAGCAC       ATTAGGTAATCGGCGCCCCA     526
  95911935              ACAAGTTCATCATCCGAGCC       CAGGGTAACACTGCCCAATCT    631
  126062819             TGAAATGGGATCAATAGG         CAAAGCAGTTGCTGGAAG       369
  155487774             CCCAAATCCTTCATCTAA         CAGTCTAACGGTTCCAAT       286
  179397807             TACTTGCGTGGCTCTGGT         AAGGCTTGGATTATTATGCTCT   403
  39913231              TCACCCCTGAGCCACAGATA       GAGGGAAAGTGGATGGTGGG     303
  117122048             TTGCATGGGTAATCAAGGGTCA     GCTGGACTGTAGCATCGTGT     610
  156186376             ACGCCTACAGGAACGAGG         GGAATGTTGGGACGGATG       450
  179436520             GAAGTGTCCCGTTTCTCA         CAGCCTTCAAACTCCTGT       409
  43748503              TGGCTTTGCTTTGGTCGTTC       AAACCAGTTGGGTGAGCAGG     520
  66291310              AGCACCCCAAGTACTGCATC       CGGGGTGTGGATGACATTGA     419
  88600890              CGACGGCCCCATCGACCTGA       CGTGCCCTTGCTGGGAGTCTGG   520
  97503827              TCGGTGTAATAGGGTTATGGTATT   TTCTTCTTTGGCCACAACCATT   399
  158636905             ACACGGACCCAGGACAAC         TTCCCTCAATGAAGGTGAAACT   403
  179406045             TTTGATTGTGGTGGTGAT         CTCCCAAGTGACTGGATAT      341

###### 

Quality of data obtained by WES.

  Sample name   Raw reads   Raw data (G)   Effective (%)   Error (%)    Q20 (%)        Q30 (%)
  ------------- ----------- -------------- --------------- ------------ -------------- --------------
  ASD-1         28464122    7.12           95.73           0.03; 0.04   95.76; 93.25   91.57; 87.61
  ASD-2         18423348    4.61           95.92           0.03; 0.04   95.79; 93.10   91.62; 87.36
  ASD-3         22964836    5.74           95.87           0.03; 0.04   95.81; 93.28   91.67; 87.70
  ASD-4         17576512    4.39           95.78           0.03; 0.04   95.72; 92.50   91.48; 86.34
  ASD-5         18637077    4.66           95.88           0.04; 0.04   95.12; 93.79   90.10; 87.89

###### 

Quantity of variants before and after filtering by 1000Genome, dbSNP, and NHLBI.

  Number of sample   Quantity of variants before filtering   Heterozygous variants   Homozygous variants   Quantity of variants after filtering
  ------------------ --------------------------------------- ----------------------- --------------------- --------------------------------------
  ASD-1              36774                                   21711                   15063                 159
  ASD-2              36031                                   20896                   15135                 142
  ASD-3              36443                                   21416                   15027                 143
  ASD-4              36240                                   21528                   14712                 133
  ASD-5              36274                                   21477                   14797                 136
  Total              181762                                  107028                  74734                 713

###### 

13 variants from WES data of 5 ASD patients by Venn analysis.

  Gene    The information of variants   The position of mutation site on a chromosome   The number of sample   Harmful prediction by SIFT/Ployphen2/Mutation Taster
  ------- ----------------------------- ----------------------------------------------- ---------------------- ------------------------------------------------------
  TTN     NM_003319: c.C70564T          179406045                                       ASD-5                  D/D/D
  TTN     NM_003319: c.G47144A          179436520                                       ASD-4                  D/D/D
  TTN     NM_003319: c.C21134G          179480499                                       ASD-2                  D/B/N
  TTN     NM_003319: c.G48662T          179435002                                       ASD-2                  D/D/D
  TTN     NM_003319: c.C76304T          179397807                                       ASD-3                  D/D/D
  HYDIN   NM_001270974: c.G7930A        70952188                                        ASD-1                  T/B/D
  HYDIN   NM_001198542: c.A2207C        71098693                                        ASD-2, ASD-3           T/P/D
  IGSF3   NM_001542: c.A619G            117156600                                       ASD-2, ASD-5           T/B/D
  IGSF3   NM_001007237: c: G3300C       117122048                                       ASD-4                  T/B/D
  ZFPM    NM_153813: c.C2359T           88600725                                        ASD-2                  T/B/D
  ZFPM    NM_153813: c.G2524A           88600890                                        ASD-5                  D/P/N
  MYH6    NM_002471: c.G985T            23871923                                        ASD-1                  D/./A
  MYH6    NM_002471: c.G2851T           23862952                                        ASD-3                  D/./A

According to SIFT, related gene was noted on tolerated (T, score \>0.5) or deleterious (D, score \<0.5). According to PolyPhen-2, related gene was noted on probably damaging (D, Polyphen-2 ≥0.909), possibly damaging (P, 0.447 ≤Polyphen-2 \<0.909), and benign (B, Polyphen-2 \<0.447). According to MutationTaster, related genes were noted on disease-causing automatic (A), disease-causing (D), polymorphism (N), and polymorphism automatic (P) (*<http://www.mutationtaster.org/>*).

###### 

21 variants associated with cardiac development or CHD obtained by Gene Ontology analysis.

  Gene      The information of variants   The position of mutation site on a chromosome   The number of sample   Harmful prediction by SIFT/Ployphen2/Mutation Taster
  --------- ----------------------------- ----------------------------------------------- ---------------------- ------------------------------------------------------
  BMP4      NM_001202: c.C125T            54418816                                        ASD-5                  T/P/D
  TTN       NM_003319: c.G48662T          179435002                                       ASD-2                  D/D/D
  DSG4      NM_001134453: c.G790A         28971146                                        ASD-5                  D/D/D
  XPO1      NM_003400: c.G2985C           61708404                                        ASD-1                  T/P/D
  TGFBR3    NM_001195683: c.G1763A        92181893                                        ASD-5                  T/B/N
  HYDIN     NM_001270974: c.G7930A        70952188                                        ASD-1                  TTN
  HYDIN     NM_001270974: c.G7930A        70952188                                        ASD-1                  T/B/D
  TENM4     NM_001098816: c.G8189C        78369224                                        ASD-1                  ./B/N
  SGCD      NM_001128209: c.A845G         156186376                                       ASD-4                  T/D/D
  MYH6      NM_002471: c.G2851T           23862952                                        ASD-3                  D/./A
  SMARCA4   NM_001128845: c.A602T         11097111                                        ASD-5                  T/P/D
  ZFPM      NM_153813: c.C2359T           88600725                                        ASD-2                  T/B/D
  ZFPM      NM_153813: c.G2524A           88600890                                        ASD-5                  D/P/N
  FOXL2     NM_023067: c.C155G            138665410                                       ASD-1                  T/P/D
  DNAH7     NM_018897: c.T6053C           196741332                                       ASD-1                  T/D/D
  DNAH17    NM_173628: c.C12828A          76422625                                        ASD-1                  D/P/D
  FIBP      NM_004214: c.G850A            65652097                                        ASD-2                  T/B/D
  ATP2B2    NM_001001331: c.A182G         10491046                                        ASD-3                  T/D/D
  ZNF638    NM_001014972: c.A254G         71576338                                        ASD-3                  D/D/D
  ALMS1     NM_015120: c.A6808G           73680465                                        ASD-3                  D/D/N
  MCHR1     NM_005297: c.G671A            41077334                                        ASD-3                  D/D/D

According to SIFT, related gene was noted on tolerated (T, score \>0.5) or deleterious (D, score \<0.5). According to PolyPhen-2, related gene was noted on probably damaging (D, Polyphen-2 ≥0.909), possibly damaging (P, 0.447 ≤Polyphen-2 \<0.909), and benign (B, Polyphen-2 \<0.447). According to MutationTaster, related genes were noted on disease-causing automatic (A), disease-causing (D), polymorphism (N), and polymorphism automatic (P) (*<http://www.mutationtaster.org/>*).

###### 

20 variants associated with cardiac development or CHD obtained by literature review and protein database.

  Gene       The information of variants   The position of mutation site on a chromosome   The number of sample   Harmful prediction by SIFT/Ployphen2/Mutation Taster
  ---------- ----------------------------- ----------------------------------------------- ---------------------- ------------------------------------------------------
  ACVR1      NM_001105: c.A275G            158636905                                       ASD-5                  T/P/D
  ARL6       NM_001278293: c.G283T         97503827                                        ASD-5                  D/P/D
  BBS1       NM_024649: c.G1067A           66291310                                        ASD-5                  T/B/D
  VEGFA      NM_001025366: c.C997T         43748503                                        ASD-5                  T/./D
  BBS9       NM_014451: c.A2389G           33573776                                        ASD-1                  T/B/D
  FMO5       NM_001144830: c.T572A         146684019                                       ASD-1                  D/D/D
  FOXL2      NM_023067: c.C155G            138665410                                       ASD-1                  T/P/D
  NSD1       NM_022455: c.A2608G           176638008                                       ASD-1                  ./D/N
  NUP188     NM_015354: c.C3047T           131756681                                       ASD-1                  D/D/D
  OBSCN      NM_001098623: c.A7301G        228467050                                       ASD-1                  T/D/D
  SOX17      NM_022454: c.A595T            55371905                                        ASD-1                  T/B/N
  XPO1       NM_003400: c.G2985C           61708404                                        ASD-1                  T/P/D
  BCOR       NM_001123384: c.T4728G        39913231                                        ASD-4                  T/B/N
  SGCD       NM_001128209: c.A845G         156186376                                       ASD-4                  T/D/D
  EP300      NM_001429: c.G2261A           41545061                                        ASD-3                  T/D/D
  FGB        NM_001184741: c.A263C         155487774                                       ASD-3                  T/B/N
  KIAA0196   NM_014846: c.A2186C           126062819                                       ASD-3                  T/D/D
  USP44      NM_001042403: c.A2134C        95911935                                        ASD-3                  D/B/D
  ZNF638     NM_001014972: c.A254G         71576338                                        ASD-3                  D/D/D
  FIBP       NM_004214: c.G850A            65652097                                        ASD-2                  T/B/D

According to SIFT, related gene was noted on tolerated (T, score \>0.5) or deleterious (D, score \<0.5). According to PolyPhen-2, related gene was noted on probably damaging (D, Polyphen-2 ≥0.909), possibly damaging (P, 0.447 ≤Polyphen-2 \<0.909), and benign (B, Polyphen-2 \<0.447). According to MutationTaster, related genes were noted on disease-causing automatic (A), disease-causing (D), polymorphism (N), and polymorphism automatic (P) (*<http://www.mutationtaster.org/>*).
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![Schematic representation of the study design and protocol. First, all variants were annotated using the ANNOVAR bioinformatics software. The normal population variant databases, including 1,000 Genomes Project, the Single Nucleotide Polymorphism database (DbSNP), and the National Heart, Lung, and Blood Institute (NHLBI) databases were used to exclude the common variants occurring with more than 1% minor allele frequency (MAF). Second, the rare variants obtained in the previous step were further analyzed using Venn analysis, gene ontology (GO) analysis, and literature review. Third, three function predictor scores, SIFT \[[@b12-medscimonit-24-1340]\], Polymorphism Phenotyping v2 (PolyPhen-2) \[[@b13-medscimonit-24-1340]\], and MutationTaster \[[@b14-medscimonit-24-1340]\] were used to predict whether the substitution of amino acids affected the function of the protein, and 33 single nucleotide variants (SNVs) were selected and validated as positive mutations by Sanger sequencing. Finally, a multiplexed MassARRAY system was performed to verify the 33 variants and three mutations with high mutation frequency, which were found to be strongly associated with atrial septal defect (ASD) (P\<0.05).](medscimonit-24-1340-g001){#f1-medscimonit-24-1340}

![Selected gene variants in patients with atrial septal defect (ASD) were validated by MassARRAY analysis. (**A**) The mutation frequency of the 138665410 variant in the *FOXL2* gene. (**B**) The mutation frequency of the 23862952 variant in the *MYH6* gene. (**C**) The mutation frequency of the 71098693 variant in the *HYDIN* gene*.* Shown in patients with ASD (**left**) and healthy subjects (**right**) in a scatter chart. These *loci* with high mutation frequency were found to be strongly associated with ASD (*P*\<0.05). Among these *loci*, variants in*FOXL2* and *MYH6* were only found in patients with ASD (*P*\<5×10^−4^). \* *P*\<0.05, \*\*\*\* *P*\<0.0005.](medscimonit-24-1340-g002){#f2-medscimonit-24-1340}

###### 

Further selected gene variants in patients with atrial septal defect (ASD) were validated by MassARRAY analysis. (**A**) The mutation frequency of the 61708404 variant in the *XPO1* gene. (**B**) The mutation frequency of the 39913231 variant in the *BCOR* gene. (**C**) The mutation frequency of the 65652097 variant in the *FIBP* gene. (**D**) The mutation frequency of the 88600890 variant in the *ZFPM* gene. (**E**) The mutation frequency of the 156186376 variant in the *SGCD* gene. (**F**) The mutation frequency of the 179480499 variant in the *TTN* gene. Shown in patients with atrial septal defect (ASD) (**left**) and healthy subjects (**right**) in a scatter chart. There was no significant difference in these six *loci* between patients with ASD and healthy subjects (P\>0.05). (NS, P\>0.05).

![](medscimonit-24-1340-g003a)

![](medscimonit-24-1340-g003b)

###### 

33 variants in 25 ASD related genes from WES data.

  Gene       The information of variants                The position of mutation site on a chromosome   The number of sample   Harmful prediction by SIFT/Ployphen-2/Mutation Taster   Bioinformatic methods        
  ---------- ------------------------------------------ ----------------------------------------------- ---------------------- ------------------------------------------------------- ----------------------- ---- ----
  TTN        NM_003319: exon178: c.C70564T: p.R23522C   179406045                                       ASD-5                  D/D/D                                                   \+                           
  TTN        NM_003319: exon154: c.G47144A: p.R15715Q   179436520                                       ASD-4                  D/D/D                                                   \+                           
  TTN        NM_003319: exon86: c.C21134G: p.T7045S     179480499                                       ASD-2                  D/B/N                                                   \+                           
  TTN        NM_003319: exon186: c.C76340T: p.P25447L   179397807                                       ASD-3                  D/D/D                                                   \+                           
  TTN        NM_003319: exon154: c.G48662T: p.G16221V   179435002                                       ASD-2                  D/D/D                                                   \+                      \+   
  HYDIN      NM_001270974: exon47: c.G7930A: p.E2644K   70952188                                        ASD-1                  T/B/D                                                   \+                      \+   
  HYDIN      NM_001198542: exon16: c.A2207C: p.H736P    71098693                                        ASD-2, ASD-3           T/P/D                                                   \+                      \+   
  IGSF3      NM_001542: exon3: c.A619G: p.S207G         117156600                                       ASD-2, ASD-5           T/B/D                                                   \+                           
  IGSF3      NM_001007237: exon10: c.G3300C: p.E1100D   117122048                                       ASD-4                  T/B/D                                                   \+                           
  ZFPM       NM_153813: exon10: c.C2359T: p.P787S       88600725                                        ASD-2                  T/B/D                                                   \+                      \+   
  ZFPM       NM_153813: exon10: c.G2524A: p.A842T       88600890                                        ASD-5                  D/P/N                                                   \+                      \+   
  MYH6       NM_002471: exon11: c.G985T: p.E329X        23871923                                        ASD-1                  D/./A                                                   \+                           
  MYH6       NM_002471: exon22: c.G2851T: p.E951X       23862952                                        ASD-3                  D/./A                                                   \+                      \+   
  FMO5       NM_001144830: exon4: c.T572A: p.I191N      146684019                                       ASD-1                  D/D/D                                                                                \+
  NSD1       NM_022455: exon5: c.A2608G: p.R870G        176638008                                       ASD-1                  ./D/N                                                                                \+
  OBSCN      NM_001098623: exon27: c.A7301G: p.H2434R   228467050                                       ASD-1                  T/D/D                                                                                \+
  FOXL2      NM_023067: exon1: c.C155G: p.A52G          138665410                                       ASD-1                  T/P/D                                                                                \+
  NUP188     NM_015354: exon28: c.C3047T: p.P1016L      131756681                                       ASD-1                  D/D/D                                                                                \+
  SOX17      NM_022454: c.A595T                         55371905                                        ASD-1                  T/B/N                                                                                \+
  XPO1       NM_003400: exon24: c.G2985C: p.K995N       61708404                                        ASD-1                  T/P/D                                                                           \+   \+
  KIAA0196   NM_014846: exon18: c.A2186C: p.N729T       126062819                                       ASD-3                  T/D/D                                                                                \+
  EP300      NM_001429: exon13: c.G2261A: p.R754H       41545061                                        ASD-3                  T/D/D                                                                                \+
  ZNF638     NM_001014972: exon2: c.A254G: p.E85G       71576338                                        ASD-3                  D/D/D                                                                                \+
  BBS1       NM_024649: exon11: c.G1067A: p.R356H       66291310                                        ASD-5                  T/B/D                                                                                \+
  ARL6       NM_001278293: exon5: c.G283T: p.D95Y       97503827                                        ASD-5                  D/P/D                                                                           \+   \+
  ACVR1      NM_001105: exon4: c.A275G: p.E92G          158636905                                       ASD-5                  T/P/D                                                                                \+
  VEGFA      NM_001025366: exon6: c.C997T: p.R333X      43748503                                        ASD-5                  T/./D                                                                                \+
  USP44      NM_001042403: exon6: c.A2134C: p.S712R     95911935                                        ASD-3                  D/B/D                                                                                \+
  FGB        NM_001184741: exon3: c.A263C: p.Y88S       155487774                                       ASD-3                  T/B/N                                                                                \+
  BCOR       NM_001123384: exon13: c.T4728G: p.D1576E   39913231                                        ASD-4                  T/B/N                                                                                \+
  SGCD       NM_001128209: exon8: c.A845G: p.Q282R      156186376                                       ASD-4                  T/D/D                                                                           \+   \+
  BBS9       NM_014451: exon19: c.A2389G: p.M797V       33573776                                        ASD-1                  T/B/D                                                                                \+
  FIBP       NM_004214: exon8: c.G850A: p.A284T         65652097                                        ASD-2                  T/B/D                                                                           \+   \+

According to SIFT, related gene was noted on tolerated (T, score \>0.5) or deleterious (D, score \<0.5). According to Ployphen-2, related gene was noted on probably damaging (D, Polyphen-2 ≥0.909), possibly damaging (P, 0.447 ≤Polyphen-2 \<0.909), and benign (B, Polyphen-2 \<0.447). According to Mutation Taster, related genes were noted on disease-causing automatic (A), disease-causing (D), polymorphism (N), and polymorphism automatic (P) (*<http://www.mutationtaster.org/>*).
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